Breathing in a harmless gas to see inside lungs: new study for cystic fibrosis
NCT ID NCT07192679
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests advanced lung imaging (MRI with xenon gas) and breathing tests to better understand lung function in people with cystic fibrosis. 60 participants will be followed over time. The goal is to see if these new methods can detect changes more precisely than standard tests.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better ways to monitor lung health in cystic fibrosis, helping doctors catch changes earlier.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly improve patient outcomes, and the new imaging methods might not prove more useful than standard tests.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2024
- Expected to finish
-
Jun 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults and children with cystic fibrosis
- Ages
-
1 year and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
General Inclusion criteria For eligibility into MAGNIFY, subjects should meet all of the following criteria: 1. A confirmed clinical diagnosis of CF, consisting of 2 confirmed disease-causing CFTR mutations along with either positive sweat chloride (\>60mmol/L, measured before starting CFTR modulator therapy) or a clinical picture consistent with CF as judged by a senior CF physician. Patients will be under one of named regional CF centres above. 2. Be able to attend the local facility for scans (Royal Hallamshire Hospital, Sheffield). For eligibility into 129Xe-MRI and lung function (cohort 1,2 and 3) 1. Aged 5 years and above 2. FEV1 \>30% predicted (best in the previous 6 months) For eligibility for cohort 1 1\. Previous participation in the MMAVIC study, with at least one prior visit where lung ventilation MRI was successfully measured. For eligibility into cohort 4 for 1H MRI only: 1\. Aged between 1 and 5 years of age General Exclusion criteria Patients who meet any of the following criteria will be excluded from the study. Further exclusions may be applied at the discretion of the principal investigators. 1. Previous lung transplant. 2. Infection with organisms of the Burkholderia cepacia complex, MRSA or Mycobacterium abscessus. 3. Pregnancy. 4. Resting SpO2 \< 90% in room air. 5. Inability to comfortably lie supine for more than 60 minutes. 6. Any contraindication(s) to MRI scanning as per the MRI questionnaire used in clinical practice by the University of Sheffield MRI unit, Royal Hallamshire Hospital. Research visit (temporary) exclusion criteria 1. Pulmonary exacerbation within 4 weeks as defined by no new treatments in that time, no clinically significant change in their symptoms or spirometry (as judged by attending physician). 2. Pregnancy. Patients who become pregnant prior to consent or during the study can remain in the study. However, no research visits will take place during pregnancy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cystic fibrosis (CF) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Sheffield MRI Unit
RECRUITINGSheffield, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Glucose sensor may flag diabetes risk in cystic fibrosis
- Can Drug-Level testing personalize cystic fibrosis treatment?
- MRI could reveal a new way to ease gut troubles in cystic fibrosis
- AI may predict lung decline in cystic fibrosis kids using muscle and balance data
- Breathing vs. beating: which technique clears lungs better in cystic fibrosis?
- Could modern CF drugs make daily inhaled treatments obsolete?